A Phase 1/2 interventional study of CHF6366 and Placebo CHF6366 in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 30th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2017, is one of 3 in phase 1/2, and was the 51st registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Chiesi Farmaceutici S.p.A. · Sites in Bulgaria
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
Chiesi Farmaceutici S.p.A. · Sites in Argentina, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–75
Chiesi Pharma AB, Nordic · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 24 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 97 across the 66 interventional studies, 300 across the 15 observational. Of the 69 that completed or were terminated, 13 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
2 of the studies in Asthma by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301736Chiesi Farmaceutici S.p.A.Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | 2027-06-03 |
| NCT06908421Chiesi Pharma AB, NordicEfficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
CHF6366 is a novel bifunctional compound displaying both muscarinic receptor antagonist and β2-adrenergic receptor agonist properties (MABA), with the potential to deliver optimal bronchodilation after inhalation dosing via two validated mechanisms in one molecule.
The study will consist of three parts:
Part 1 will consit of two cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF 6366
Part 2 will consist of four cohorts of asthmatic subjects to assess the saftey, tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6366
Part 3 will consist of one cohort of COPD patients to asess safety, tolerability of a single dose of CHF6366 in an active and placebo controlled design
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1
Part 2
Part 3
Exclusion Criteria:
Part1
Part 2
Part 3
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CHF6366
Drug: Placebo CHF6366
Drug: umeclidinium bromide and vilanterol trifenatate
Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject) Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days Drug: CHF6366 (Part 3) Single dose of CHF6366
Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects) Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days Drug: Placebo (Part 3) Single dose of placebo matching CHF6366
Drug pages: Umeclidinium bromide · Vilanterol trifenatate
Part 3 Single dose
Adverse Events
Time frame: Part 1 from Day 1 until day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)
Vital signs
Systolic, diastolic Blood Pressure
Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)
Change in Holter ECG parameters
HR, PR, QRS, QTcF, QT
Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1 until day 8, Part 3 from Day 1 until Day 3 (per each period)
Change in Holter parameters
Time frame: Part 1 from Day 1 until Day 3, Part 2 from Day 1, until Day 8, Part 3 from Day 1 until Day 3(per each period)
Change in FEV1
Forced expiratory capacity in the first second
Time frame: Part 1 drom Day 1 until Day 3, Part 2 from Day 1 until Day 8
Change in Laboratiry parameters
clinical chemistry, haematology and urinanalysis
Time frame: Part 1 Day -1 and Day 3, Part 2 Day -2 and Day 8, Part 3 Day -1 and Day 2
Change in serum potassium level
Time frame: Part 1 Day 1, Part 2 Day 1 and Day 7, Part 3 Day 1
Area under the plasma concentration vs time curve
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Peak plasma concentration (Cmax)
maximum plasma concentration of CHF6366
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Time to reach the maximum plasma concentration (tmax)
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Elimination half-life (t1/2)
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Clearance (CL/F)
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Volume of distribution (Vz/F)
Time frame: Part 1 Day 1 until Day 3, Part 2 Day 1 , Part 3 Day 1 until Day 3 (per each period)
Area under the plasma concentration vs time curve during selected dosing interval
Time frame: Part 2 Day 7
Peak plasma concentration during selected dosing (Cmaxss)
Time frame: Part 2 Day 7
Value of minimum plasma concentration post dosing at selected dosing interval (Cminss)
Time frame: Part 2 Day 7
Time of minimum plasma concentration post dosing at selected dosing interval (Tminss)
Time frame: Part 2 Day 7
Time to reach the maximum plasma concentration at selected dosing interval(tmaxss)
Time frame: Part 2 Day 7
Clearance at selected dosing interval (CL/Fss)
Time frame: Part 2 Day 7
Volume of distribution at selected dosing interval (Vz/Fss)
Time frame: Part 2 Day 7
Accumulation ratio (Rac)
Time frame: Part 2 Day 7
Steady state concentration (Css)
Time frame: Part 2 Day 7
Urinary excretion (Ae)
Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)
fraction excreted (fe)
Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)
Clearance (CLr)
Time frame: Part 1 from Day 1 until Day 3, Part 2 Day 1 and Day 7, Part 3 from Day 1 until Day 3 (per each period)
Plan to share: No
Ran from Dec 2017 to primary completion in Apr 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.